Overview

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

Status:
Recruiting

Trial end date:
2028-05-31

Target enrollment:

Participant gender:

Summary

This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Jazz Pharmaceuticals

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Pembrolizumab